Bellerophon Therapeutics Future Growth
Future criteria checks 0/6
Bellerophon Therapeutics's revenue and earnings are forecast to decline at 106.7% and 38.2% per annum respectively while EPS is expected to decline by 35.6% per annum.
Key information
-38.2%
Earnings growth rate
-35.6%
EPS growth rate
Biotechs earnings growth | 32.0% |
Revenue growth rate | -106.7% |
Future return on equity | n/a |
Analyst coverage | Low |
Last updated | 04 Aug 2023 |
Recent future growth updates
Recent updates
Earnings and Revenue Growth Forecasts
Date | Revenue | Earnings | Free Cash Flow | Cash from Op | Avg. No. Analysts |
---|---|---|---|---|---|
12/31/2024 | N/A | -20 | N/A | -17 | 1 |
12/31/2023 | 6 | -11 | N/A | -22 | 1 |
6/30/2023 | 6 | -12 | -11 | -11 | N/A |
3/31/2023 | 6 | -11 | -10 | -10 | N/A |
12/31/2022 | N/A | -20 | -18 | -18 | N/A |
9/30/2022 | N/A | -19 | -17 | -17 | N/A |
6/30/2022 | N/A | -19 | -18 | -18 | N/A |
3/31/2022 | N/A | -18 | -20 | -20 | N/A |
12/31/2021 | N/A | -18 | -23 | -23 | N/A |
9/30/2021 | N/A | -21 | -25 | -25 | N/A |
6/30/2021 | N/A | -25 | -25 | -25 | N/A |
3/31/2021 | N/A | -25 | -23 | -23 | N/A |
12/31/2020 | N/A | -25 | -20 | -20 | N/A |
9/30/2020 | N/A | -21 | -16 | -16 | N/A |
6/30/2020 | N/A | -17 | -15 | -15 | N/A |
3/31/2020 | N/A | -17 | -15 | -15 | N/A |
12/31/2019 | N/A | -13 | -13 | -13 | N/A |
9/30/2019 | N/A | -10 | -14 | -14 | N/A |
6/30/2019 | N/A | 5 | -16 | -16 | N/A |
3/31/2019 | N/A | -2 | -17 | -17 | N/A |
12/31/2018 | N/A | 3 | -15 | -15 | N/A |
9/30/2018 | N/A | -20 | -16 | -16 | N/A |
6/30/2018 | N/A | -39 | -14 | -14 | N/A |
3/31/2018 | N/A | -32 | -13 | -13 | N/A |
12/31/2017 | N/A | -55 | -16 | -16 | N/A |
9/30/2017 | N/A | -38 | -14 | -14 | N/A |
6/30/2017 | N/A | -35 | -14 | -14 | N/A |
3/31/2017 | N/A | -36 | N/A | -14 | N/A |
12/31/2016 | N/A | -24 | N/A | -17 | N/A |
9/30/2016 | N/A | -27 | N/A | -32 | N/A |
6/30/2016 | N/A | -34 | N/A | -40 | N/A |
3/31/2016 | N/A | -41 | N/A | -44 | N/A |
12/31/2015 | N/A | -46 | N/A | -46 | N/A |
9/30/2015 | N/A | -48 | N/A | -41 | N/A |
6/30/2015 | N/A | -53 | N/A | -45 | N/A |
3/31/2015 | N/A | -58 | N/A | -49 | N/A |
12/31/2014 | N/A | -60 | N/A | -71 | N/A |
9/30/2014 | N/A | -64 | N/A | -71 | N/A |
3/31/2014 | N/A | -62 | N/A | -72 | N/A |
12/31/2013 | N/A | -62 | N/A | -57 | N/A |
Analyst Future Growth Forecasts
Earnings vs Savings Rate: 6L7A is forecast to remain unprofitable over the next 3 years.
Earnings vs Market: 6L7A is forecast to remain unprofitable over the next 3 years.
High Growth Earnings: 6L7A is forecast to remain unprofitable over the next 3 years.
Revenue vs Market: 6L7A's revenue is expected to decline over the next 3 years (-106.7% per year).
High Growth Revenue: 6L7A's revenue is forecast to decline over the next 3 years (-106.7% per year).
Earnings per Share Growth Forecasts
Future Return on Equity
Future ROE: Insufficient data to determine if 6L7A's Return on Equity is forecast to be high in 3 years time